<span item_type="fundamental" item_id="4704df8742c6d60750be2ba80fc1d008" counter_id="ST/US/EVOK" env="prod"></span><span item_type="announcement" item_id="549306531250118401" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 3.752 M, missing the estimate of USD 3.796 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD -0.62.</p><p></p><h3>Segment Revenue</h3><ul><li>Net product sales for Q2 2025 were $3.8 million, a 47% increase from $2.6 million in Q2 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1403708/000095017025108411/evok-ex99_1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Net loss for Q2 2025 was - $1.6 million, or - $0.62 per share, compared to - $1.3 million, or - $0.93 per share, in Q2 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1403708/000095017025108411/evok-ex99_1.htm"></span></li><li>Selling, general, and administrative expenses increased to $5.1 million in Q2 2025 from $3.7 million in Q2 2024, primarily due to higher profit-sharing with EVERSANA and increased professional fees.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1403708/000095017025108411/evok-ex99_1.htm"></span></li><li>Total operating expenses for Q2 2025 were $5.3 million, up from $3.8 million in Q2 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1403708/000095017025108411/evok-ex99_1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the six months ended June 30, 2025, was - $1.6 million, compared to - $3.4 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1403708/000095017025108411/evok-ex99_1.htm"></span></li><li>Cash and cash equivalents as of June 30, 2025, were $12.1 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1403708/000095017025108411/evok-ex99_1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>New prescribers increased by 20% year-over-year, indicating growing clinical adoption of GIMOTI.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1403708/000095017025108411/evok-ex99_1.htm"></span></li><li>Refill rates remained steady at approximately 70%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1403708/000095017025108411/evok-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Evoke Pharma confirms its full-year 2025 net product sales guidance of approximately $16 million, representing up to a 60% increase over 2024. This guidance reflects trends in prescription growth, refill rates, and expanded pharmacy access, while considering external factors such as macroeconomic conditions and supply chain constraints.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1403708/000095017025108411/evok-ex99_1.htm"></span></li></ul>

Evoke Pharma | 8-K: FY2025 Q2 Revenue Misses Estimate at USD 3.752 M